{"entity": "researcher", "timestamp": "2026-08-23T09:27:18.562Z", "family": "Miliotis", "given": "Tasso", "initials": "T", "orcid": "0000-0003-4917-0724", "affiliations": ["Translational Science and Experimental Medicine, Cardiovascular, Renal and Metabolism, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden."], "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/researcher/a0d5ba9b546949db95c9b8597bd1fe7e.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/researcher/a0d5ba9b546949db95c9b8597bd1fe7e"}}, "publications": [{"entity": "publication", "iuid": "80fc82d4a197449ba117c3eb3d8d9c0f", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/80fc82d4a197449ba117c3eb3d8d9c0f.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/80fc82d4a197449ba117c3eb3d8d9c0f"}}, "title": "Patient-Centric Quantitative Microsampling for Accurate Determination of Urine Albumin to Creatinine Ratio (UACR) in a Clinical Setting.", "authors": [{"family": "L\u00f6fgren", "given": "Lars", "initials": "L"}, {"family": "von Euler Chelpin", "given": "Marianne", "initials": "M"}, {"family": "Bhat", "given": "Maria", "initials": "M"}, {"family": "Althage", "given": "Magnus", "initials": "M"}, {"family": "Hober", "given": "Andreas", "initials": "A", "orcid": "0000-0001-8947-2562", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/06cbc187628340278395a00ab9dd6c89.json"}}, {"family": "Edfors", "given": "Fredrik", "initials": "F"}, {"family": "Ruckh", "given": "Tim", "initials": "T"}, {"family": "Challis", "given": "Benjamin", "initials": "B"}, {"family": "Davidsson", "given": "Pia", "initials": "P", "orcid": "0000-0002-4775-5828", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/a62589743acc4ae3967b343bf4bb3d33.json"}}, {"family": "Miliotis", "given": "Tasso", "initials": "T", "orcid": "0000-0003-4917-0724", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/a0d5ba9b546949db95c9b8597bd1fe7e.json"}}], "type": "journal article", "published": "2024-03-01", "journal": {"title": "J Appl Lab Med", "issn": "2576-9456", "volume": "9", "issue": "2", "pages": "329-341", "issn-l": null}, "abstract": "Developing and implementing new patient-centric strategies for drug trials lowers the barrier to participation for some patients by reducing the need to travel to research sites. In early chronic kidney disease (CKD) trials, albuminuria is the key measure for determining treatment effect prior to pivotal kidney outcome trials.\n\nTo facilitate albuminuria sample collection outside of a clinical research site, we developed 2 quantitative microsampling methods to determine the urinary albumin to creatinine ratio (UACR). Readout was performed by LC-MS/MS.\n\nFor the Mitra device the within-batch precision (CV%) was 2.8% to 4.6% and the between-batch precision was 5.3% to 6.1%. Corresponding data for the Capitainer device were 4.0% to 8.6% and 6.7% to 9.0%, respectively. The storage stability at room temperature for 3 weeks was 98% to 103% for both devices. The recovery for the Mitra and Capitainer devices was 104% (SD 7.0%) and 95 (SD 7.4%), respectively. The inter-assay comparison of UACR assessment generated results that were indistinguishable regardless of microsampling technique. The accuracy based on LC-MS/MS vs analysis of neat urine using a clinical chemistry analyzer was assessed in a clinical setting, resulting in 102 \u00b1 8.0% for the Mitra device and 95 \u00b1 10.0% for the Capitainer device.\n\nBoth UACR microsampling measurements exhibit excellent accuracy and precision compared to a clinical chemistry analyzer using neat urine. We applied our patient-centric sampling strategy to subjects with heart failure in a clinical setting. Precise UACR measurements using quantitative microsampling at home would be beneficial in clinical drug development for kidney therapies.", "doi": "10.1093/jalm/jfad111", "pmid": "38113397", "labels": [], "xrefs": [{"db": "pii", "key": "7479657"}], "notes": [], "created": "2026-08-20T09:42:02.090Z", "modified": "2026-08-20T09:42:02.234Z"}, {"entity": "publication", "iuid": "4bc155f82d0c4e57ab67cbb059dcbc5c", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/4bc155f82d0c4e57ab67cbb059dcbc5c.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/4bc155f82d0c4e57ab67cbb059dcbc5c"}}, "title": "Targeted proteomics using stable isotope labeled protein fragments enables precise and robust determination of total apolipoprotein(a) in human plasma.", "authors": [{"family": "Hober", "given": "Andreas", "initials": "A", "orcid": "0000-0001-8947-2562", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/06cbc187628340278395a00ab9dd6c89.json"}}, {"family": "Rekanovic", "given": "Mirela", "initials": "M"}, {"family": "Forsstr\u00f6m", "given": "Bj\u00f6rn", "initials": "B"}, {"family": "Hansson", "given": "Sara", "initials": "S"}, {"family": "Kotol", "given": "David", "initials": "D"}, {"family": "Percy", "given": "Andrew J", "initials": "AJ"}, {"family": "Uhl\u00e9n", "given": "Mathias", "initials": "M"}, {"family": "Oscarsson", "given": "Jan", "initials": "J"}, {"family": "Edfors", "given": "Fredrik", "initials": "F"}, {"family": "Miliotis", "given": "Tasso", "initials": "T", "orcid": "0000-0003-4917-0724", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/a0d5ba9b546949db95c9b8597bd1fe7e.json"}}], "type": "journal article", "published": "2023-02-15", "journal": {"title": "PLoS ONE", "issn": "1932-6203", "volume": "18", "issue": "2", "pages": "e0281772", "issn-l": "1932-6203"}, "abstract": "Lipoprotein(a), also known as Lp(a), is an LDL-like particle composed of apolipoprotein(a) (apo(a)) bound covalently to apolipoprotein B100. Plasma concentrations of Lp(a) are highly heritable and vary widely between individuals. Elevated plasma concentration of Lp(a) is considered as an independent, causal risk factor of cardiovascular disease (CVD). Targeted mass spectrometry (LC-SRM/MS) combined with stable isotope-labeled recombinant proteins provides robust and precise quantification of proteins in the blood, making LC-SRM/MS assays appealing for monitoring plasma proteins for clinical implications. This study presents a novel quantitative approach, based on proteotypic peptides, to determine the absolute concentration of apo(a) from two microliters of plasma and qualified according to guideline requirements for targeted proteomics assays. After optimization, assay parameters such as linearity, lower limits of quantification (LLOQ), intra-assay variability (CV: 4.7%) and inter-assay repeatability (CV: 7.8%) were determined and the LC-SRM/MS results were benchmarked against a commercially available immunoassay. In summary, the measurements of an apo(a) single copy specific peptide and a kringle 4 specific peptide allow for the determination of molar concentration and relative size of apo(a) in individuals.", "doi": "10.1371/journal.pone.0281772", "pmid": "36791076", "labels": [], "xrefs": [{"db": "pmc", "key": "PMC9931122"}, {"db": "pii", "key": "PONE-D-22-14035"}], "notes": [], "created": "2026-08-20T12:44:20.753Z", "modified": "2026-08-20T12:44:20.850Z"}]}